Article Versions Notes

Tomita T, Fukui H, Morishita D, Mori S, Oshima T, Shinzaki S, Miwa H. Efficacy of Serotonin Type 3 Receptor Antagonist Ramosetron on Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)-Like Symptoms in Patients with Quiescent Inflammatory Bowel Disease: A Randomized, Double-Blind, Placebo-Controlled Trial. Journal of Clinical Medicine. 2022; 11(23):6882. https://doi.org/10.3390/jcm11236882

Tomita, Toshihiko, Hirokazu Fukui, Daisuke Morishita, Sumire Mori, Tadayuki Oshima, Shinichiro Shinzaki, and Hiroto Miwa. 2022. "Efficacy of Serotonin Type 3 Receptor Antagonist Ramosetron on Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)-Like Symptoms in Patients with Quiescent Inflammatory Bowel Disease: A Randomized, Double-Blind, Placebo-Controlled Trial" Journal of Clinical Medicine 11, no. 23: 6882. https://doi.org/10.3390/jcm11236882

Tomita, T., Fukui, H., Morishita, D., Mori, S., Oshima, T., Shinzaki, S., & Miwa, H. (2022). Efficacy of Serotonin Type 3 Receptor Antagonist Ramosetron on Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)-Like Symptoms in Patients with Quiescent Inflammatory Bowel Disease: A Randomized, Double-Blind, Placebo-Controlled Trial. Journal of Clinical Medicine, 11(23), 6882. https://doi.org/10.3390/jcm11236882